Benign prostatic hyperplasia (BPH) is one of the most common urinary and reproductive system diseases in elderly men. The preliminary research of the research group found that mast cells are cells that promote the progression of BPH, and the commonly used mast cell membrane stabilizer and TGF - β pathway inhibitor tranilast significantly inhibited the increase in prostate volume in animal experiments, which is considered to have potential applications in the treatment of BPH. This study plans to include 30 patients with medium to large volume BPH and experimentally explore the efficacy and safety of tranilast in the treatment of medium to large volume BPH.
Patients with benign prostatic hyperplasia aged 55 to 75 years old;
The patient's prostate volume is greater than 40mL;
There is urinary obstruction, with an International Prostate Symptom Score (IPSS) greater than or equal to 8 points, and a maximum urinary flow rate of less than 15ml/s (urinary flow rate is not measured in patients with indwelling catheters).
Urinary disorders caused by neurogenic diseases;
Acute urinary tract infections have not been effectively controlled;
There are factors of lower urinary tract obstruction other than BPH, such as urethral stricture;
History of radiation therapy or surgery in the lower urinary tract or pelvic cavity;
Yifeng Jing
Lead sponsor
Shanghai General Hospital, China
Sponsor institution